KS_TAN
:
i dont really expect surprises in this quarter result. japan approval gotten in late sep, fda approval gotten in oct. ema approval expecting by end of year. sale and royalty fee shall be log in for 4th quarter...so forecast is what i am look for for the prospect in tis company.
KS_TAN : i dont really expect surprises in this quarter result. japan approval gotten in late sep, fda approval gotten in oct. ema approval expecting by end of year. sale and royalty fee shall be log in for 4th quarter...so forecast is what i am look for for the prospect in tis company.
风光3265 : @KS_TAN所以这个礼拜不会有惊喜，我们要等到年底了吗
KS_TAN : 不是真的。需要监视多头对预测的反应。盘后交易非常关键。现在价格接近40。多头将第三次尝试突破40。如果足够强劲，它可能会造成空头挤压并会大放异彩... 但是，不要低估HF的强度来抑制定价... 这种情况甚至在美国食品药品管理局批准之前就已经发生了...
KS_TAN : 说实话，这只股票很难上手... 我一直在观察价格抑制而不是真正的抛售... 但我相信基本面最终会是双赢。chemocentryx是转机故事股票... 现在 chemocentryx 已经开始在全球范围内将其药物商业化... 因此，从中期到长期来看，它肯定会翻一番或三倍。当前的价格将成为历史。